IL40685A - Pharmaceutical compositions for the dissolution of renal calculi containing magnesium and citrate ions and their preparation - Google Patents

Pharmaceutical compositions for the dissolution of renal calculi containing magnesium and citrate ions and their preparation

Info

Publication number
IL40685A
IL40685A IL40685A IL4068572A IL40685A IL 40685 A IL40685 A IL 40685A IL 40685 A IL40685 A IL 40685A IL 4068572 A IL4068572 A IL 4068572A IL 40685 A IL40685 A IL 40685A
Authority
IL
Israel
Prior art keywords
composition according
citrate
weight
ion source
magnesium
Prior art date
Application number
IL40685A
Other versions
IL40685A0 (en
Original Assignee
Chinoin Gyogyszer Es Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet
Publication of IL40685A0 publication Critical patent/IL40685A0/en
Publication of IL40685A publication Critical patent/IL40685A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (21)

1. An oral pharmaceutical composition £>r the prevention or relief of renal calculi, which comprises as active ingredients at lea* one magnesium ion source, at least one citrate ion source and vitamin-Bg, said magnesium ion source and citrate ion source in the proportions of 2-20$ and 66-98.5$ respectively based on the weight of active ingredients, and optionally solid or liquid pharmaceutical carriers or diluents.
2. A composition according to Claim 1 which comprises 2-10$ on said basis of said at least one magnesium ion source.
3. A composition according to Claim 2 which comprises 5-10$ on said basis of said at least one magnesium ion source.
4. A composition according to any of the preceding claims which comprises 92-98.5$ on said basis of said at least one citrate ion source.
5. composition according to any of the preceding claims which comprises 0.1-1$ on said basis of vitamin-B^.
6. A composition according to any of the preceding claims which comprises as citrate ion source citric acid, alkali metal citrates or alkaline earth metal citrates.
7. A composition according to Claim 6, which comprises as citrate ion source sodium citrate or potassium citrate.
8. A composition according to any of Claims 1-6, which, comprises as citrate ion source a mixture of citric acid and an alkali metal carbonate or alkali metal hydrogen carbonate.
9. A composition according to any of the preceding claims which comprises as magnesium ion source an organic or inorganic magnesium salt o magnesium oxide. 40635/2
10. A composition according to Claim 9, which comprises as magnesium ion source magnesium acetate or magnesium carbonate.
11. A composition according to any of the preceding claims, which comprises magnesium citrate as both a citrate and a magnesium ion source.
12. A composition according to any of the preceding claims, which comprises as aotive ingredients 92-98.5$ by weight of at least one citrate ion source, 5-10 by weight of at least one magnesium ion source and 0.1-1$ by weight of vitamin-Bg, based on the total weight of said aotive ingredients.
13. · A composition according to Claims 1 and 5, which comprises as active ingredients 10-40$ by weight of trisodium citrate, 20-40 by weight of tripotassium citrate, 0.1-30$ by weight of citric acid, 2-20 by weight of magnesium citrate and 0.01-1.5$ by weight of vitamin-Bg, based on the total weight of said active ingredients.
14. A composition according to Claim 13, which comprises on said basis 25-35 by weight of trisodium citrate, 35-40 by weight of tripotassium citrate, 10-14$ by weight of citric acid, 6-9$ by weight of magnesium citrate and 0.2-0.4$ by weight of vitamin-Bg.
15. A composition according to any of the preceding claims, in the form of tablets, pills, coated pills, dragees, granules, powders, solutions, suspensions or emulsions.
16. A composition according to any of the preceding claims containing essentially no carrier or diluent.
17. A composition according to Claim 12 containing essentially no carrier or diluent. 40685/2
18. * A composition according to Claim 13 containing essentially no carrier or diluent.
19. - A composition according to Claim 14 containing essentially no carrier or diluent.
20. A composition according to any of the preceding claims in association with written directions to administer or take said composition for the prevention or relief of renal calculi.
21. A composition according to Claim 1 substantially as described herein with reference to any one of the Examples. HE/AJ
IL40685A 1971-11-08 1972-10-27 Pharmaceutical compositions for the dissolution of renal calculi containing magnesium and citrate ions and their preparation IL40685A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUCI1185A HU165181B (en) 1971-11-08 1971-11-08

Publications (2)

Publication Number Publication Date
IL40685A0 IL40685A0 (en) 1972-12-29
IL40685A true IL40685A (en) 1976-08-31

Family

ID=10994422

Family Applications (1)

Application Number Title Priority Date Filing Date
IL40685A IL40685A (en) 1971-11-08 1972-10-27 Pharmaceutical compositions for the dissolution of renal calculi containing magnesium and citrate ions and their preparation

Country Status (9)

Country Link
AT (1) AT332531B (en)
CA (1) CA978479A (en)
CS (1) CS217603B1 (en)
DD (1) DD100631A1 (en)
DE (1) DE2252665A1 (en)
GB (1) GB1403900A (en)
HU (1) HU165181B (en)
IL (1) IL40685A (en)
SU (1) SU1009467A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826642C2 (en) 1978-06-19 1987-04-23 Dr. Madaus & Co, 5000 Köln Oral urolithiasis agent
DE3046580A1 (en) * 1980-12-11 1982-07-01 Leskovar, Peter, Dr.-Ing., 8000 München Prophylactic and curative treatment of urinary calculi - by admin. of organic acid, dye, metal oxide, etc.
DE3728814A1 (en) * 1987-08-28 1989-03-30 Lentia Gmbh SOLUTION FOR USE AS A RINSING LIQUID IN THE DESTRUCTION OF NON-BODY DEPOSITS IN HUMAN AND ANIMAL TISSUES OR BODIES
JP2545479B2 (en) * 1989-02-07 1996-10-16 ミッション ファーマカル カンパニー，インコーポレーテッド Pharmaceutical composition
CA1326040C (en) * 1989-11-16 1994-01-11 Neill B. Walsdorf Magnesium-potassium citrate
DE4409949C2 (en) * 1994-03-23 1996-11-21 Madaus Ag Use of calcium alkali citrates for the prophylaxis and treatment of degenerative diseases of the bone structure
DE10028167B4 (en) * 2000-06-09 2004-02-19 Storch, Rüdiger, Dr. Use of calcium salts to counteract the formation of oxalate stones
US8603989B2 (en) 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
FR2967576B1 (en) 2010-11-18 2013-07-12 Advicenne Pharma PHARMACEUTICAL COMPOSITION COMPRISING KREBS CYCLE PRECURSOR SALT, IN PARTICULAR CITRATE SALT, AND ITS USE AS A MEDICINAL PRODUCT
FR2967578B1 (en) 2010-11-18 2012-12-28 Advicenne Pharma PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS AND USE THEREOF FOR THE TREATMENT OF CYSTINURIA
MX352660B (en) * 2013-03-15 2017-12-04 Univ New York Citrate containing beverage.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328304A (en) * 1964-07-31 1967-06-27 Guardian Chemical Corp Chelating agents and methods for their manufacture
FR2019261A1 (en) * 1969-03-19 1970-07-03 Melon Jean Marie Treatment of oxalic lithiase with succinic - acid and its derivs

Also Published As

Publication number Publication date
DD100631A1 (en) 1973-10-05
AT332531B (en) 1976-10-11
GB1403900A (en) 1975-08-28
DE2252665C2 (en) 1987-09-10
SU1009467A1 (en) 1983-04-07
DE2252665A1 (en) 1973-05-10
IL40685A0 (en) 1972-12-29
CS217603B1 (en) 1983-01-28
CA978479A (en) 1975-11-25
ATA925372A (en) 1976-01-15
HU165181B (en) 1974-07-27

Similar Documents

Publication Publication Date Title
IL40685A (en) Pharmaceutical compositions for the dissolution of renal calculi containing magnesium and citrate ions and their preparation
GB1131007A (en) Improvements in or relating to aqueous solutions of oxytetracycline
GB1518364A (en) Pharmaceutical composition
US4016090A (en) Stable bleaching composition
IE43901L (en) Pharmaceutical compositions
US2918400A (en) Sanitizing compositions
US5010069A (en) Stable liquid form of 5-aminosalicylic acid
GB1226394A (en)
JPS5241613A (en) Granular or powdered detergent compositions
GB1256968A (en)
GB1500408A (en) Process for the preparation of catalysts and supported catalysts
ES359336A1 (en) Uterotropic composition
GB1221038A (en) Improvements in effervescent tablet compositions
GB1505738A (en) Tabletting processes
JPS5569515A (en) Pharmaceutical composition
GB1451352A (en) Method of suppressing mildew using a composition containing an alkanoic acid salt
US5006516A (en) Method for the prophylaxis of cardiac infarctions and the prevention of reinfarctions
CH651207A5 (en) PHARMACEUTICAL COMPOSITION TO COMBAT PLATELET AGGREGATION.
GB1361779A (en) Vincamine salt and its use as a pharmaceutical composition
GB829686A (en) Submerged arc welding flux composition
GB1219300A (en) Improvements in or relating to the preparation of an iron melt having a low sulphur content
GB1437788A (en) Therapeutic compositions
Rostoker et al. Fast freezing by atomization for aluminum alloy development
ES400335A1 (en) A method for the preparation of a humedecible dust composition of a halogenated complex of quaternary dihalide. (Machine-translation by Google Translate, not legally binding)
GB1509778A (en) Pharmaceutical composition and dosage units thereof